<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820285</url>
  </required_header>
  <id_info>
    <org_study_id>11-PP-10</org_study_id>
    <nct_id>NCT02820285</nct_id>
  </id_info>
  <brief_title>Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH</brief_title>
  <official_title>Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent epidemiological studies in France showed a high prevalence of obesity (14.5%) and its&#xD;
      strong increase in the last 20 years. Among the many complications associated with obesity,&#xD;
      liver complications (steatosis and steatohepatitis [NASH]) are among the most common.&#xD;
      Semaphorins were described in the early 1990. More than 20 types of these proteins have been&#xD;
      reported to date. These proteins were used for neural development. Since many functions have&#xD;
      also been described. The semaphorins are involved in numerous physiological or&#xD;
      physiopathological processes (cardiac morphogenesis, vascular growth, tumor progression), the&#xD;
      regulation of immune cells and liver fibrosis. Preliminary studies have allowed to show that&#xD;
      dendritic cells infiltrate adipose tissue and initiate the activation of T cells and&#xD;
      inflammation. Immune semaphorin are new players in the regulation of inflammation and immune&#xD;
      reactions.&#xD;
&#xD;
      The role of immune semaphorin in regulating inflammation in the two compartments (liver and&#xD;
      adipose tissue) could be a crucial step that could lead to more severe liver damage. Its&#xD;
      dysregulation could explain NASH injuries. The goal is to identify a new mode of regulation&#xD;
      of cellular homeostasis in the fatty liver disease. These factors may serve as diagnostic&#xD;
      markers or future therapeutic targets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the staging of liver fibrosis</measure>
    <time_frame>Day 0</time_frame>
    <description>The investigators determine the stage of liver fibrosis by histological study of biopsies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the expression of level of semaphorin</measure>
    <time_frame>Day 0</time_frame>
    <description>The investigators determine by technic of Reverse Transcription Polymerase Chain Reaction (RT-PCR) the expression of level of semaphorin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the composition of immunity cells</measure>
    <time_frame>Day 0</time_frame>
    <description>The investigators determine the composition of immunity cells by Immunohistochemical and biochemical analyses (Western Blotting)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Morbid obese patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with overweight, steatosis and steatohepatitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of the staging of fibrosis liver</intervention_name>
    <description>The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies</description>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Morbid obese patients</arm_group_label>
    <arm_group_label>Patients with overweight, steatosis and steatohepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Determine the expression level of semaphorin</intervention_name>
    <description>The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,</description>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Morbid obese patients</arm_group_label>
    <arm_group_label>Patients with overweight, steatosis and steatohepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Determination of the composition of immunity cells</intervention_name>
    <description>The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting&#xD;
)</description>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Morbid obese patients</arm_group_label>
    <arm_group_label>Patients with overweight, steatosis and steatohepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Morbid obese patients&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female aged 18-65 years&#xD;
&#xD;
          -  Patients with body mass index justifying a surgery for obesity (BMI ≥ 40 kg / m2 or&#xD;
             BMI ≥ 35 kg / m2 with comorbidities)&#xD;
&#xD;
          -  Consumption of alcohol &lt;20 g / d&#xD;
&#xD;
          -  Patients affiliated to a social security insurance&#xD;
&#xD;
          -  Patients who signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemochromatosis&#xD;
&#xD;
          -  Toxic hepatitis&#xD;
&#xD;
          -  Deficiency of alpha-1-antitrypsin&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Liver Autoimmune disease (primary biliary cirrhosis, autoimmune hepatitis)&#xD;
&#xD;
          -  Hepatitis B, C&#xD;
&#xD;
          -  Drug-induced hepatitis&#xD;
&#xD;
          -  Presence of HIV status&#xD;
&#xD;
          -  Corticosteroids, amiodarone, valproic acid, tamoxifen, anti-inflammatory drugs, lipid&#xD;
             lowering agents, testosterone agonists or beta-adrenergic antagonists, orlistat.&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Incarcerated patients or patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert TRAN, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

